A drug approved for multiple myeloma and lymphoma has shown remarkable potential in shrinking tumors in non-small cell lung cancer (NSCLC) with KRAS mutations. Research led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center highlights a breakthrough in targeted cancer treatment. These findings, published in Clinical Cancer Research, pave the way for more effective …
Continue reading “Repurposed Drug Shows Promise for KRAS-Mutated Lung Cancer”